Therapy-related acute lymphoblastic leukemia with MLL rearrangement following treatment of Burkitt's leukemia

Leukemia and Lymphoma

Volumn 46, Issue 6, 2005, Pages 925-927

  Millot, Frederic ^a   Brizard, Francoise ^b   Sorel, Nathalie ^b   Preudhomme, Claude ^c   Cividin, Marie ^b   Guilhot, Francois ^a   Brizard, Andre ^b  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b Poitiers University Hospital   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Burkitt's leukemia; Children; DNA topoisomerase II inhibitors; Therapy related leukemia

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; HYDROCORTISONE; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISONE; VINCRISTINE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ASTHENIA; BLAST CELL; BLOOD CELL COUNT; BONE MARROW BIOPSY; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME ANALYSIS; CHROMOSOME Q BAND; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 4; DRUG MEGADOSE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA REMISSION; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SPLENOMEGALY; WEIGHT REDUCTION;

BURKITT LYMPHOMA; CHILD; CHROMOSOMES, HUMAN, PAIR 4; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; MALE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TIME FACTORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 21844463040     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500052248     Document Type: Article

References (15)

1. Pedersen-Bjergaard J, Christiansen DH, Andersen M, Skovby F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia 2002;16:2177-2184.
2. Felix CA. Leukemias related to treatment with DNA topoisomerase inhibitors. Med Pediatr Oncol 2001;36:525-535.
3. Patte C, Auperin A, Michon J et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.
4. Repp R, Borkhardt A, Haupt E et al. Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DAN-fragment analysis. Leukemia 1995;9:210-215.
5. Nasr F, Macintyre E, Venuat AM, Bayle C, Carde P, Ribrag V. Translocation t(4;11) (q21;q23) and MLL gene rearrangement acute lymphoblastic leukaemia secondary to antitopoisomerase anticancer agents. Leuk Lymphoma 1997;25:399-401.
6. Al-Homaidhi AM, Patterson B, Rubin S, Upton JH. Acute lymphoblastic leukaemia with multiple cytogenetic abnormalities secondary to treatment of Ewing's sarcoma. Leuk Res 1999;23:593-596.
7. Lennard A, Jackson GH, Carey PJ, Bown N, Middleton P, Proctor S. Secondary acute lymphoblastic leukaemia with t(4;11) translocation following treatment for Hodgkin's disease: case report and review of the literature. Leukemia 1991;5:624-627.
8. Auxenfants E, Morel P, Lai JL et al. Secondary acute lymphoblastic leukaemia with t(4;11): report of 2 cases and review of the literature. Ann Hematol 1992;65:143-146.
9. Casteels K, Renard M, Van Gool S, Uyttebroeck A. Secondary acute lymphoblastic leukemia in a child three years after treatment for medulloblastoma. Med Pediatr Oncol 2001;36:390-391.
10. Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol 2001;114:539-543.
11. Strissel Broeker PL, Super HG, Thirman MJ et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 1996;87:1912-1922.
12. Le Deley MC, Leblanc T, Shamsaldin A et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol 2003;21:1074-1081.
13. Chessels JM. Pitfalls in the diagnosis of childhood leukaemia. Br J Haematol 2001;114:506-511.
14. Navid F, Mosijczuk AD, Head DR et al. Acute lymphoblastic leukemia with the (8; 14) (q24; q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group Experience. Leukemia 1999;13:135-141.
15. Reiter A, Schrappe M, Tiemann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin - Frankfurt- Munster group trial NHL-BFM. Blood 1999;94:3294-3306.